DCM-R
BGUi010-A
General
Cell Line |
|
hPSCreg name | BGUi010-A |
Cite as: | BGUi010-A (RRID:CVCL_A4ZN) |
Alternative name(s) |
DCM-R
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines |
HDZi001-A (hiPSC NP0039) Donor's gene variants: TMEM43 Donor diseases: arrhythmogenic right ventricular dysplasia 5 |
Last update | 4th February 2021 |
User feedback | |
Provider |
|
Generator | Ben Gurion University of the Negev (BGU) |
Owner | Ben Gurion University of the Negev (BGU) |
Distributors | |
External Databases |
|
BioSamples | SAMEA8093254 |
Cellosaurus | CVCL_A4ZN |
Wikidata | Q107113457 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
Sex | male |
Ethnicity | Bedouin |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA8152180 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | Dr. Aviva Levitas, Soroka medical center |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | Dr. Aviva Levitas, Soroka medical center |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | No information |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | No |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell type |
Dermal fibroblasts are the major cell type in dermis and are commonly accepted as terminally differentiated cells.
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Medium |
Other medium:
Base medium: NutriStem® hPSC XF
Main protein source: Serum concentration: % |
Characterisation
Analysis of Undifferentiated Cells
Differentiation Potency
In vitro spontaneous differentiation
Marker | Expressed |
AFP |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
ACTA2 |
Yes |
In vitro spontaneous differentiation
Marker | Expressed |
NEFL |
Yes |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.